Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $4.7 million.

  • SAB Biotherapeutics' Depreciation & Amortization (CF) fell 22.22% to $700,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 37.08%. This contributed to the annual value of $4.7 million for FY2024, which is 27.18% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Depreciation & Amortization (CF) stood at $4.7 million for FY2024, which was up 27.18% from $3.7 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Depreciation & Amortization (CF) registered a high of $4.7 million during FY2024, and its lowest value of $383,142 during FY2020.
  • For the 3-year period, SAB Biotherapeutics' Depreciation & Amortization (CF) averaged around $3.9 million, with its median value being $3.7 million (2023).
  • Data for SAB Biotherapeutics' Depreciation & Amortization (CF) shows a peak YoY soared of 288.53% (in 2021) over the last 5 years.
  • SAB Biotherapeutics' Depreciation & Amortization (CF) (Yearly) stood at $383,142 in 2020, then surged by 288.53% to $1.5 million in 2021, then surged by 114.97% to $3.2 million in 2022, then increased by 15.62% to $3.7 million in 2023, then climbed by 27.18% to $4.7 million in 2024.